Home › FDA Grants QIDP And Fast Track Designation To CD101 Topical, Cidara Therapeutics' Novel Antifungal Product Candidate
 

Keywords :   


FDA Grants QIDP And Fast Track Designation To CD101 Topical, Cidara Therapeutics' Novel Antifungal Product Candidate

2016-06-01 05:41:19| drugdiscoveryonline Home Page

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, recently announced that the U.S. Food and Drug Administration (FDA) has designated the company’s novel antifungal product candidate, CD101 topical, as a Qualified Infectious Disease Product (QIDP), with Fast Track status for its development program

Tags: product fast track candidate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Still no sign of herd rebuilding
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
More »